RARA CRAFT DATABASE for FDA Medical Devices
PMAP160045S046

FDA DEVICE FACTS

Oncomine Dx Target Test

Life Technologies Corporation

Verified FDA Record identity for medical-device development research. This overview uses only fields stated in the FDA Record and is not a Device Description.医療機器開発の調査用に、確認済みの FDA Record の識別情報を示しています。この概要は FDA Record に記載された項目だけによるもので、機器説明ではありません。

DECISION DATEOctober 17, 2024PRODUCT CODEPQP

Indications for use

The Oncomine™ Dx Target Test is a qualitative in vitro diagnostic test that uses targeted high-throughput, parallel-sequencing technology to detect single nucleotide variants (SNVs), deletions, and insertions in 23 genes from DNA and fusions in ROS1 and RET from RNA

isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples from patients with non-small cell lung cancer (NSCLC), IDH1 SNVs from FFPE tumor tissue samples from patients with cholangiocarcinoma (CC), BRAF V600E mutations from FFPE tumor tissue samples from patients with anaplastic thyroid cancer (ATC), IDH1 and IDH2 SNVs from FFPE tumor tissue samples from patients with astrocytoma (AC) and oligodendroglioma (OG), RET SNVs, multi-nucleotide variants (MNVs), and deletions from DNA isolated from FFPE tumor tissue samples from patients with medullary thyroid cancer (MTC) and RET fusions from RNA isolated from FFPE tumor tissue samples from patients with thyroid cancer (TC) using the Ion PGM™ Dx System. The test is indicated as a companion diagnostic to aid in selecting NSCLC, CC, ATC, AC, OG, MTC and TC patients for treatment with the targeted therapies listed in Table 1 in accordance with the approved therapeutic product labeling. Table 1. List of variants for therapeutic use by indication Tissue type Gene Variant Targeted therapy NSCLC BRAF BRAF V600E mutations TAFINLAR® (dabrafenib) in combination with MEKINIST® (trametinib) EGFR EGFR L858R mutation, EGFR exon 19 deletions IRESSA ® (gefitinib) EGFR EGFR exon 20 insertions RYBREVANT™ (amivantamab-vmjw) ERBB2/HER2 ERBB2/HER2 activating mutations (SNVs and exon 20 insertions) ENHERTU ® (fam-trastuzumab deruxtecan-nxki) RET RET fusions GAVRETO™ (pralsetinib) RETEVMO ® (selpercatinib) ROS1 ROS1 fusions XALKORI® (crizotinib) CC IDH1 IDH1 R132C, IDH1 R132G, IDH1 R132H IDH1 R132L, and IDH1 R132S mutations TIBSOVO® (ivosidenib) ATC BRAF BRAF V600E mutations TAFINLAR® (dabrafenib) in combination with MEKINIST® (trametinib) MTC RET RET mutations (SNVs, MNVs, and deletions) RETEVMO ® (selpercatinib) TC RET RET fusions RETEVMO® (selpercatinib) AC and OG IDH1, IDH2 IDH1 R132C, IDH1 R132G, IDH1 R132H, IDH1 R132L, IDH1 R132S, IDH2 R172M, IDH2 R172K, IDH2 R172W, IDH2 R172S, and IDH2 R172G mutations VORANIGO® (vorasidenib)

Safe and effective use has not been established for selecting therapies using this device for the variants listed in tissue types other than those in Table 1. Results other than those listed in Table 1 are indicated for use only in patients who have already been considered for all appropriate therapies (including those listed in Table 1). Analytical performance using NSCLC specimens has been established for the variants listed in Table 2. Table 2. List of Variants with Established Analytical Performance Only Gene Variant ID/t ype Amino acid change Nucleotide Change KRAS COSM512 p.Gly12Phe c.34_35delGGinsTT KRAS COSM516 p.Gly12Cys c.34G>T MET COSM707 p.Thr1010lle c.3029C>T PIK3CA COSM754 p.Asn345Lys c.1035T>A The test is not indicated to be used for standalone diagnostic purposes, screening, monitoring, risk assessment, or prognosis.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: September 2, 2026